Related topics: Industry Drivers
Wyeth is cutting back on its early stage R&D efforts to focus on oncology, inflammation, vaccines, metabolic diseases, musculoskeletal problems and neuroscience.
The move, which is part of the firm’s Project Impact restructuring strategy is in keeping with refocusing efforts made by rivals such as Pfizer, Eli Lilly and Bristol-Myers Squibb in recent months.
Wyeth spokesman Michael Lampe told Reuters that the plans were not a cost-reduction exercise and would affect neither its level of R&D spending or personnel.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2009 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions
Food & Beverage: Food & Beverage Development - Europe | Food & Beverage Development - North America | Food Marketing and Retailing | Food Processing & Packaging | Food Safety & Quality Control | Food and Beverage in Asia Pacific | Industrial Baking & Snacks | Beverage Technology & Markets | Confectionery & Biscuit Processing | Dairy Processing & Markets | Prepared Food and Meat Processing Nutrition: Supplements & Nutrition - Europe | Supplements & Nutrition - North America Pharmaceutical: Pharmaceutical Technology | Contract Research, Manufacturing & Clinical Trials Cosmetics: Cosmetics Formulation & Packaging - North America | Cosmetics Formulation & Packaging - Europe
© 2000/2009 - Decision News Media SAS - All right reserved.
